Table of Contents
Advances in Psychiatry
Volume 2015, Article ID 520784, 6 pages
http://dx.doi.org/10.1155/2015/520784
Research Article

Valproate Prescribing in Women of Childbearing Age: An Audit of Clinical Practice

1Pennine Care NHS Foundation Trust, Royal Oldham Hospital, Oldham, Lancashire OL1 2JH, UK
2Pennine Care NHS Foundation Trust, Birch Hill Hospital, Rochdale OL12 9QB, UK

Received 16 June 2014; Revised 13 January 2015; Accepted 22 January 2015

Academic Editor: Holly A. Garriock

Copyright © 2015 Harini Atturu and Adedeji Odelola. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Tomson, D. Battino, E. Bonizzoni et al., “Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry,” The Lancet Neurology, vol. 10, no. 7, pp. 609–617, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. European Medicines Agency, “PRAC recommends strengthening the restrictions on the use of valproate in women and girls. Review 612389,” London, UK, European Medicines Agency, 2014.
  3. National Institute for Health and Care Excellence (NICE), “Antenatal and postnatal mental health: clinical management and service guidance,” in Clinical Guideline 192, National Institute for Health and Care Excellence, 2014. View at Google Scholar
  4. S. J. Moore, P. Turnpenny, A. Quinn et al., “A clinical study of 57 children with fetal anticonvulsant syndromes,” Journal of Medical Genetics, vol. 37, no. 7, pp. 489–497, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Adab, U. Kini, J. Vinten et al., “The longer term outcome of children born to mothers with epilepsy,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 11, pp. 1575–1583, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. K. J. Meador, G. A. Baker, N. Browning et al., “Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs,” The New England Journal of Medicine, vol. 360, no. 16, pp. 1597–1605, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Gaily, E. Kantola-Sorsa, V. Hiilesmaa et al., “Normal intelligence in children with prenatal exposure to carbamazepine,” Neurology, vol. 62, no. 1, pp. 28–32, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Vinten, N. Adab, U. Kini, J. Gorry, J. Gregg, and G. A. Baker, “Neuropsychological effects of exposure to anticonvulsant medication in utero,” Neurology, vol. 64, no. 6, pp. 949–954, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Kantola-Sorsa, E. Gaily, M. Isoaho, and M. Korkman, “Neuropsychological outcomes in children of mothers with epilepsy,” Journal of the International Neuropsychological Society, vol. 13, no. 4, pp. 642–652, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. R. L. Bromley, G. Mawer, J. Clayton-Smith, and G. A. Baker, “Autism spectrum disorders following in utero exposure to antiepileptic drugs,” Neurology, vol. 71, no. 23, pp. 1923–1924, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Ornoy, “Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy,” Reproductive Toxicology, vol. 22, no. 2, pp. 214–226, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. G. M. Goodwin, “Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British association for psychopharmacology,” Journal of Psychopharmacology, vol. 23, no. 4, pp. 346–388, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. O. Diav-Citrin, S. Shechtman, B. Bar-Oz, D. Cantrell, J. Arnon, and A. Ornoy, “Pregnancy outcome after In Utero exposure to valproate: evidence of dose relationship in teratogenic effect,” CNS Drugs, vol. 22, no. 4, pp. 325–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. R. F. McKnight, M. Adida, K. Budge, S. Stockton, G. M. Goodwin, and J. R. Geddes, “Lithium toxicity profile: a systematic review and meta-analysis,” The Lancet, vol. 379, no. 9817, pp. 721–728, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. Epilepsy Guidance Group, Primary Care Guidance for the Management of Women taking Antiepileptic Drugs, Epilepsy Guidance Group, 2011.
  16. National Institute for Health and Clinical Excellence (NICE), Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care, NICE Clinical Guidelines, no. 38, NICE, 2006.
  17. J. Hayes, P. Prah, I. Nazareth et al., “Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995–2009,” PLoS ONE, vol. 6, no. 12, Article ID e28725, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. National Institute for Health and Clinical Excellence (NICE), NICE Implementation Uptake Report: Bipolar Disorder Clinical Guideline 38, NICE, 2009.
  19. D. A. Adedinsewo, D. J. Thurman, Y. H. Luo, R. S. Williamson, O. A. Odewole, and G. P. Oakley Jr., “Valproate prescriptions for nonepilepsy disorders in reproductive-age women,” Birth Defects Research, Part A—Clinical and Molecular Teratology, vol. 97, no. 6, pp. 403–408, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. A. J. Lloyd, C. L. Harrison, I. N. Ferrier, and A. H. Young, “The pharmacological treatment of bipolar affective disorder: practice is improving but could still be better,” Journal of Psychopharmacology, vol. 17, no. 2, pp. 230–233, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Langan, A. Perry, and M. Oto, “Teratogenic risk and contraceptive counselling in psychiatric practice: analysis of anticonvulsant therapy,” BMC Psychiatry, vol. 13, article 234, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. F. J. E. Vajda, S. Hollingworth, J. Graham et al., “Changing patterns of antiepileptic drug use in pregnant Australian women,” Acta Neurologica Scandinavica, vol. 121, no. 2, pp. 89–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Ackers, F. M. C. Besag, A. Wade, M. L. Murray, and I. C. K. Wong, “Changing trends in antiepileptic drug prescribing in girls of child-bearing potential,” Archives of Disease in Childhood, vol. 94, no. 6, pp. 443–447, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. A. C. Viguera, L. S. Cohen, S. Bouffard, T. H. Whitfield, and R. J. Baldessarini, “Reproductive decisions by women with bipolar disorder after prepregnancy psychiatric consultation,” The American Journal of Psychiatry, vol. 159, no. 12, pp. 2102–2104, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Mace and D. Taylor, “Improving adherence to NICE guidance for bipolar illness: valproate use in women of childbearing potential,” The Psychiatric Bulletin, vol. 35, no. 2, pp. 63–67, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Mothi, C. Chambers, S. Shora, and A. Jabeen, “2305—Audit on effects of mood stabilisers on women's health—informed decision making,” European Psychiatry, vol. 28, supplement 1, p. 1, 2013. View at Publisher · View at Google Scholar
  27. A. Wieck, S. Rao, K. Sein, and P. M. Haddad, “A survey of antiepileptic prescribing to women of childbearing potential in psychiatry,” Archives of Women's Mental Health, vol. 10, no. 2, pp. 83–85, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. L. James, T. R. E. Barnes, P. Lelliott, D. Taylor, and C. Paton, “Informing patients of the teratogenic potential of mood stabilizing drugs: a case note review of the practice of psychiatrists,” Journal of Psychopharmacology, vol. 21, no. 8, pp. 815–819, 2007. View at Publisher · View at Google Scholar · View at Scopus